Update on Biosimilar Insulins: A US Perspective-Reference-Cited by-同舟云学术

Update on Biosimilar Insulins: A US Perspective

Published:2020-07-17 Issue:4 Volume:34 Page:505-512
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Zhang Rong M.,Puri Ritika,McGill Janet B.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s40259-020-00431-0.pdf

Reference35 articles.

1. National Diabetes Statistics Report 2020. cdc.gov. https://www.cdc.gov/diabetes/library/features/diabetes-stat-report.html (2020). Accessed 18 May 2020.

2. Rosenfeld L. Insulin: discovery and Controversy. Clin Chem. 2002;48(12):2270–88.

3. The Rising Cost of Insulin. Diabetes Forecast. https://www.diabetesforecast.org/2016/mar-apr/rising-costs-insulin.html (2016). Accessed 19 Sept 2019.

4. Petersen MP. Economic costs of diabetes in the US in 2017. Diabetes Care. 2018;41(5):917–28.

5. Hua X, Carvalho N, Tew M, et al. Expenditures and prices of antihyperglycemic medications in the United States: 2002–2013. JAMA. 2016;315(13):1400–2. https://doi.org/10.1001/jama.2016.0126.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study;Diabetes, Obesity and Metabolism;2024-04

2. Global Barriers to Accessing Off-Patent Endocrine Therapies: A Renaissance of the Orphan Disease?;The Journal of Clinical Endocrinology & Metabolism;2023-10-17

3. Utilization, user characteristics, and adverse outcomes of insulin glargine originators and follow-on drug in patients with diabetes in the United States;Journal of Managed Care & Specialty Pharmacy;2023-07

4. The Nuances Surrounding Insulin Prescribing;Clinical Diabetes;2023-03-28

5. Biosimilars: Promising and Rapidly Emerging Biotherapeutics;Novel Technologies in Biosystems, Biomedical & Drug Delivery;2023